DBV Technologies Shares Surge 6.4% Midday, Breaking the 3 Euro Resistance
The stock of the French biotech company specialized in food allergy treatments gained 6.44% at midday this Wednesday, December 10, trading at 3.14 euros compared to 2.95 euros at the previous day's close. This performance is part of a spectacular upward trajectory, with the stock having already increased by 9.16% on Monday and 9.06% on Tuesday. Trading volumes remain contained with 0.57% of the capital exchanged since the opening, reflecting a movement mainly driven by technical dynamics and investor anticipation. Over the week, DBV Technologies has soared by 39.25%, while its quarterly performance has reached 107.7%. The annual surge peaks at 372.2%, positioning the stock among the highest gains in the Paris market in 2025. This rise occurs as the CAC 40 hovers around 8,100 points, highlighting the dynamic
Technically, the stock has now broken through its major resistance set at 3.08 euros, thus opening up new room for progression. The stock is trading well above its 50-day moving average, set at 2.51 euros, confirming the strength of the short-term bullish trend. This growing gap between the stock price and the moving average indicates that buyers are clearly dominating the market and that the momentum remains favorable. The RSI stands at 66, a level that reflects significant investor enthusiasm without yet reaching the overbought zone beyond 70. This indicator suggests that the stock still has room to progress before entering overheating. The MACD shows a positive setup with a histogram at 0.06, indicating that the MACD line (0.01) has crossed its signal line (-0.05). This bullish crossover confirms the strengthening of the buying momentum and validates the continuation of the upward trend. Volatility remains high at 25.24% over a month, characteristic of biotechs awaiting crucial clinical results. The support is now at 2.26 euros, a level that should contain any potential pullback. With a negative beta of -0.22, the stock shows a low correlation with the market, explaining its independent trajectory.
The phase 3 VITESSE trial assesses the efficacy and safety of the Viaskin Peanut patch in 654 subjects aged 4 to 7 years allergic to peanuts, involving individuals spread across 86 sites in the United States, Canada, Europe, the United Kingdom, and Australia, making VITESSE the largest therapeutic intervention study in peanut allergy. The release of preliminary results, expected by the end of December, will be a critical milestone for the company and could condition the filing of a marketing authorization application with the FDA. DBV Technologies closed the third quarter of 2025 with a cash balance and cash equivalents of 69.8 million dollars, allowing the company to fund operations until the third quarter of 2026. The French biotech, listed in Paris and on the Nasdaq, develops treatments for food allergies through its epicutaneous immunotherapy platform Viaskin, which allows the administration of antigens through the skin without ingestion. In this context of anticipation, the continuous progression of the stock reflects the optimism of investors regarding the regulatory and commercial prospects of the Viaskin Peanut patch. Breaking the 3 euro resistance marks a significant symbolic and technical milestone, which could pave the way for further gains if clinical results prove positive.
